Phillip Md Et Al Frost Acquires 30,000 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was bought at an average cost of $3.38 per share, with a total value of $101,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $10,373,054.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 19th, Phillip Md Et Al Frost purchased 40,000 shares of Opko Health stock. The stock was bought at an average cost of $3.51 per share, with a total value of $140,400.00.
  • On Thursday, March 15th, Phillip Md Et Al Frost purchased 61,000 shares of Opko Health stock. The stock was bought at an average cost of $3.32 per share, with a total value of $202,520.00.
  • On Monday, March 12th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was bought at an average cost of $3.48 per share, with a total value of $87,000.00.
  • On Wednesday, March 7th, Phillip Md Et Al Frost purchased 75,000 shares of Opko Health stock. The stock was bought at an average cost of $3.29 per share, with a total value of $246,750.00.
  • On Friday, March 2nd, Phillip Md Et Al Frost purchased 364,800 shares of Opko Health stock. The stock was bought at an average cost of $2.94 per share, with a total value of $1,072,512.00.
  • On Wednesday, February 21st, Phillip Md Et Al Frost purchased 172,500 shares of Opko Health stock. The stock was bought at an average cost of $3.63 per share, with a total value of $626,175.00.
  • On Friday, February 9th, Phillip Md Et Al Frost purchased 185,000 shares of Opko Health stock. The stock was bought at an average cost of $3.83 per share, with a total value of $708,550.00.
  • On Wednesday, February 7th, Phillip Md Et Al Frost purchased 78,000 shares of Opko Health stock. The stock was bought at an average cost of $4.22 per share, with a total value of $329,160.00.
  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $4.14 per share, with a total value of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were acquired at an average cost of $4.30 per share, with a total value of $236,500.00.

OPK stock opened at $3.27 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.98 and a current ratio of 1.14. Opko Health Inc. has a 52 week low of $2.66 and a 52 week high of $8.40. The firm has a market capitalization of $1,851.86, a P/E ratio of -5.84 and a beta of 1.60.

Institutional investors and hedge funds have recently modified their holdings of the stock. RK Asset Management LLC increased its position in shares of Opko Health by 8.4% during the fourth quarter. RK Asset Management LLC now owns 932,752 shares of the biotechnology company’s stock worth $4,570,000 after purchasing an additional 72,209 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of Opko Health by 611.8% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after purchasing an additional 1,242,272 shares in the last quarter. X Square Capital LLC purchased a new stake in shares of Opko Health during the fourth quarter worth approximately $2,363,000. Boulegeris Investments Inc. increased its position in shares of Opko Health by 19.3% during the fourth quarter. Boulegeris Investments Inc. now owns 228,780 shares of the biotechnology company’s stock worth $1,121,000 after purchasing an additional 36,950 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new stake in shares of Opko Health during the third quarter worth approximately $583,000. Hedge funds and other institutional investors own 23.38% of the company’s stock.

Several research analysts have recently weighed in on OPK shares. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. JPMorgan Chase & Co. downgraded Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price for the company. in a research note on Friday, March 2nd. BidaskClub downgraded Opko Health from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. ValuEngine downgraded Opko Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the stock a “buy” rating in a research note on Thursday, March 1st. Four analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Opko Health currently has a consensus rating of “Hold” and a consensus price target of $11.29.

WARNING: This article was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296217/phillip-md-et-al-frost-acquires-30000-shares-of-opko-health-inc-opk-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FIG Partners Comments on Central Valley Community Bancorp’s FY2019 Earnings
FIG Partners Comments on Central Valley Community Bancorp’s FY2019 Earnings
Jupiter Fund Management’s  “Hold” Rating Reiterated at Numis Securities
Jupiter Fund Management’s “Hold” Rating Reiterated at Numis Securities
Howdens Joinery’s  “Add” Rating Reiterated at Numis Securities
Howdens Joinery’s “Add” Rating Reiterated at Numis Securities
Hammerson  Upgraded by Barclays to “Equal weight”
Hammerson Upgraded by Barclays to “Equal weight”
Liberum Capital Reiterates Hold Rating for Intu Properties
Liberum Capital Reiterates Hold Rating for Intu Properties
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion


© 2006-2018 Ticker Report. Google+.